Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry
- Glecaprevir/pibrentasvir, a pangenotypic, direct-acting antiviral combination approved for chronic hepatitis C virus treatment, has limited real-world evidence supporting 8-week therapy in compensated cirrhosis. We investigated effectiveness and safety of 187 hepatitis C virus-infected, treatment-naïve, patients with compensated cirrhosis receiving 8-week glecaprevir/pibrentasvir therapy in the German Hepatitis C-Registry between 2 August 2017 and 1 January 2020. Sustained virologic response was 98.4% (127/129) in the per-protocol analysis (excluding patients lost to follow-up or who discontinued treatment due to compliance) and was 85.8% (127/148) in patients with data available in an intention-to-treat analysis. Nineteen patients were lost to follow-up; nine genotype 3 patients, nine nongenotype 3 patients and one mixed genotype patient. One patient relapsed, and one died, unrelated to treatment. Adverse events (>5%) were fatigue and headache. Two serious adverse events occurred; no adverse events resulted in drug discontinuation. An 8-week glecaprevir/pibrentasvir therapy was effective and well-tolerated in this real-world analysis.
Author: | Hartwig KlinkerORCiD, Uwe Naumann, Martin RössleORCiDGND, Thomas BergORCiDGND, Mark Bondin, Kristina Lohmann, Bettina Koenig, Stefan ZeuzemGND, Markus CornbergORCiDGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-858037 |
DOI: | https://doi.org/10.1111/liv.14937 |
ISSN: | 1478-3231 |
Parent Title (English): | Liver international |
Publisher: | Wiley-Blackwell |
Place of publication: | Oxford |
Document Type: | Article |
Language: | English |
Date of Publication (online): | 2021/05/09 |
Date of first Publication: | 2021/05/09 |
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Release Date: | 2024/08/15 |
Tag: | 8 weeks; cirrhosis; glecaprevir; hepatitis C virus; pibrentasvir |
Volume: | 41 |
Page Number: | 5 |
First Page: | 1518 |
Last Page: | 1522 |
Note: | The design, study conduct, analysis and financial support of the study were provided by AbbVie. |
Institutes: | Medizin |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Licence (German): | ![]() |